INTERVENTION 1:	Intervention	0
Everolimus	Intervention	1
everolimus	CHEBI:68478	0-10
Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy). Anti-estrogen therapy will be administered at the US Food and Drug Administration (FDA) prescribed doses.	Intervention	2
everolimus	CHEBI:68478	0-10
anti-estrogen	CHEBI:50751	99-112
anti-estrogen	CHEBI:50751	279-292
anti-estrogen	CHEBI:50751	303-316
patient	HADO:0000008,OAE:0001817	136-143
tamoxifen	CHEBI:41774	170-179
fulvestrant	CHEBI:31638	181-192
anastrozole	CHEBI:2704	194-205
letrozole	CHEBI:6413	207-216
exemestane	CHEBI:4953	218-228
food	CHEBI:33290	356-360
drug administration	OAE:0000011	365-384
Everolimus	Intervention	3
everolimus	CHEBI:68478	0-10
Exemestane: Anti-estrogen therapy	Intervention	4
exemestane	CHEBI:4953	0-10
anti-estrogen	CHEBI:50751	12-25
Tamoxifen: Anti-estrogen therapy	Intervention	5
tamoxifen	CHEBI:41774	0-9
anti-estrogen	CHEBI:50751	11-24
Fulvestrant: Anti-estrogen therapy	Intervention	6
fulvestrant	CHEBI:31638	0-11
anti-estrogen	CHEBI:50751	13-26
Anastrozole: Anti-estrogen therapy	Intervention	7
anastrozole	CHEBI:2704	0-11
anti-estrogen	CHEBI:50751	13-26
Letrozole: Anti-estrogen therapy	Intervention	8
letrozole	CHEBI:6413	0-9
anti-estrogen	CHEBI:50751	11-24
Toremifine: Anti-estrogen therapy	Intervention	9
anti-estrogen	CHEBI:50751	12-25
Inclusion Criteria:	Eligibility	0
Histologic diagnosis of unresectable, locally recurrent or MBC.	Eligibility	1
recurrent	HP:0031796	46-55
ER and/or PR-positive tumors with staining by immunohistochemistry (IHC) based on the most recent biopsy.	Eligibility	2
immunohistochemistry	BAO:0000415	46-66
Only 1 previous chemotherapy regimen for MBC. Patients progressing while receiving adjuvant endocrine therapy or progressing <12 months from completion of adjuvant endocrine therapy are eligible.	Eligibility	3
adjuvant	CHEBI:60809	83-91
adjuvant	CHEBI:60809	155-163
Progressed on anti-estrogen therapy (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy) defined as:	Eligibility	4
anti-estrogen	CHEBI:50751	14-27
anti-estrogen	CHEBI:50751	146-159
tamoxifen	CHEBI:41774	37-46
fulvestrant	CHEBI:31638	48-59
anastrozole	CHEBI:2704	61-72
letrozole	CHEBI:6413	74-83
exemestane	CHEBI:4953	85-95
Recurrence while on, or within 12 months of end of anti-estrogen therapy for early stage breast cancer, or	Eligibility	5
anti-estrogen	CHEBI:50751	51-64
breast cancer	DOID:1612	89-102
Progression while on, or within one month of anti-estrogen therapy for locally advanced or metastatic breast cancer.	Eligibility	6
month	UO:0000035	36-41
anti-estrogen	CHEBI:50751	45-58
breast cancer	DOID:1612	102-115
Note: No washout for anti-estrogen therapy required. Anti-estrogen therapy does not have to be the last treatment prior to study entry.	Eligibility	7
anti-estrogen	CHEBI:50751	21-34
anti-estrogen	CHEBI:50751	53-66
Post-menopausal or pre/peri-menopausal women on tamoxifen. LHRH agonists may be used to render ovarian suppression with postmenopausal ranges of estradiol or FSH per institutional guidelines.	Eligibility	8
tamoxifen	CHEBI:41774	48-57
estradiol	CHEBI:23965	145-154
HER2-negative breast cancer, defined as follows:	Eligibility	9
breast cancer	DOID:1612	14-27
Fluorescent In Situ Hybridization (FISH)-negative (FISH ratio <2.0), or	Eligibility	10
ratio	UO:0000190	56-61
IHC 0-1+, or	Eligibility	11
IHC 2-3+ AND FISH-negative (FISH ratio <2.0).	Eligibility	12
ratio	UO:0000190	33-38
Measureable disease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or evaluable bone lesions, lytic or mixed, in absence of measureable disease by RECIST criteria.	Eligibility	13
disease	DOID:4,OGMS:0000031	12-19
disease	DOID:4,OGMS:0000031	179-186
mixed	BAO:0002107	146-151
Adequate hematologic, hepatic and renal function.	Eligibility	14
function	BAO:0003117,BFO:0000034	40-48
International normalized ratio (INR) 1.5 or prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (WNL) of the institution (if patient is not on anti-coagulation therapy).	Eligibility	15
ratio	UO:0000190	25-30
prothrombin time	CMO:0000211	44-60
time	PATO:0000165	56-60
time	PATO:0000165	89-93
patient	HADO:0000008,OAE:0001817	150-157
Age  18 years.	Eligibility	16
age	PATO:0000011	0-3
ECOG Performance Status score of 0-2.	Eligibility	17
Life expectancy of  12 weeks.	Eligibility	18
Exclusion Criteria:	Eligibility	19
Previous therapy or known intolerance/hypersensitivity with any approved or investigational mTOR inhibitor (e.g., temsirolimus, everolimus, sirolimus).	Eligibility	20
mtor inhibitor	CHEBI:68481	92-106
temsirolimus	CHEBI:79699	114-126
everolimus	CHEBI:68478	128-138
sirolimus	CHEBI:9168	117-126
sirolimus	CHEBI:9168	140-149
Patients who are 21 days after their most recent chemotherapy and have not recovered from side effects.	Eligibility	21
Use of an investigational drug 21 days or 5 half-lives (whichever is shorter) prior to the first dose of everolimus. For investigational drugs for which 5 half-lives is 21 days, a minimum of 10 days between termination of the investigational drug and administration of everolimus is required.	Eligibility	22
drug	CHEBI:23888	26-30
drug	CHEBI:23888	137-141
drug	CHEBI:23888	242-246
everolimus	CHEBI:68478	105-115
everolimus	CHEBI:68478	269-279
Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered 28 days or limited field radiation for palliation 7 days for metastatic disease prior to first dose of everolimus or has not recovered from side effects of such therapy.	Eligibility	23
radiotherapy	OAE:0000235	11-23
disease	DOID:4,OGMS:0000031	168-175
everolimus	CHEBI:68478	199-209
Previously untreated brain metastases. Patients who have received radiation or surgery for brain metastases are eligible if there is no evidence of central nervous system (CNS) disease progression, and at least 2 weeks have elapsed since treatment. Patients are not permitted to receive enzyme inducing anti-epileptic drugs (EIAEDs) during the study and should not be receiving chronic corticosteroid therapy for CNS metastases.	Eligibility	24
brain	UBERON:0000955	21-26
brain	UBERON:0000955	91-96
surgery	OAE:0000067	79-86
central nervous system	UBERON:0001017	148-170
disease	DOID:4,OGMS:0000031	177-184
enzyme	BAO:0000279	287-293
chronic	HP:0011010	378-385
corticosteroid	CHEBI:50858	386-400
Patients with known active hepatitis B (HBV) or hepatitis C (HCV) infection. Patients with risk factors for hepatitis must have HBV DNA and HCV RNA testing by PCR, and are ineligible if these tests are positive.	Eligibility	25
active	PATO:0002354	20-26
hepatitis b	DOID:2043	27-38
hepatitis c	DOID:1883	48-59
hepatitis	HP:0012115,DOID:2237	27-36
hepatitis	HP:0012115,DOID:2237	48-57
hepatitis	HP:0012115,DOID:2237	108-117
dna	BAO:0000269	132-135
rna	BAO:0000270	144-147
Patients receiving immunization with attenuated live vaccines within 1 week of study entry or during study period.	Eligibility	26
week	UO:0000034	71-75
NOTE: There are additional inclusion/exclusion criteria. The study center will determine patient eligibility and respond to any questions.	Eligibility	27
patient	HADO:0000008,OAE:0001817	89-96
Outcome Measurement:	Results	0
Median Progression Free Survival (PFS)	Results	1
median	BAO:0002174	0-6
PFS is defined as the time from Day 1 of study drug administration to disease progression as defined by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1 criteria, or death on study. Participants who are alive and free from disease progression will be censored at the date of last radiologic tumor assessment. Participants who receive non-protocol therapy (subsequent therapy) prior to incurring an event will be censored at the date of last tumor assessment prior to the start of subsequent therapy. Participants who do not have a post-baseline tumor assessment will be censored at the date of first treatment (Day 1).	Results	2
time	PATO:0000165	22-26
day	UO:0000033	32-35
day	UO:0000033	628-631
drug administration	OAE:0000011	47-66
disease	DOID:4,OGMS:0000031	70-77
disease	DOID:4,OGMS:0000031	240-247
death	OAE:0000632	183-188
Time frame: up to 3 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Everolimus	Results	5
everolimus	CHEBI:68478	17-27
Arm/Group Description: Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy). Anti-estrogen therapy will be administered at the US Food and Drug Administration (FDA) prescribed doses.	Results	6
everolimus	CHEBI:68478	23-33
anti-estrogen	CHEBI:50751	122-135
anti-estrogen	CHEBI:50751	302-315
anti-estrogen	CHEBI:50751	326-339
patient	HADO:0000008,OAE:0001817	159-166
tamoxifen	CHEBI:41774	193-202
fulvestrant	CHEBI:31638	204-215
anastrozole	CHEBI:2704	217-228
letrozole	CHEBI:6413	230-239
exemestane	CHEBI:4953	241-251
food	CHEBI:33290	379-383
drug administration	OAE:0000011	388-407
Everolimus	Results	7
everolimus	CHEBI:68478	0-10
Exemestane: Anti-estrogen therapy	Results	8
exemestane	CHEBI:4953	0-10
anti-estrogen	CHEBI:50751	12-25
Tamoxifen: Anti-estrogen therapy	Results	9
tamoxifen	CHEBI:41774	0-9
anti-estrogen	CHEBI:50751	11-24
Fulvestrant: Anti-estrogen therapy	Results	10
fulvestrant	CHEBI:31638	0-11
anti-estrogen	CHEBI:50751	13-26
Anastrozole: Anti-estrogen therapy	Results	11
anastrozole	CHEBI:2704	0-11
anti-estrogen	CHEBI:50751	13-26
Letrozole: Anti-estrogen therapy	Results	12
letrozole	CHEBI:6413	0-9
anti-estrogen	CHEBI:50751	11-24
Toremifine: Anti-estrogen therapy	Results	13
anti-estrogen	CHEBI:50751	12-25
Overall Number of Participants Analyzed: 36	Results	14
Median (95% Confidence Interval)	Results	15
median	BAO:0002174	0-6
Unit of Measure: months  7.2        (4.1 to 10.0)	Results	16
Adverse Events 1:	Adverse Events	0
Total: 15/48 (31.25%)	Adverse Events	1
Anemia * 1/48 (2.08%)	Adverse Events	2
anemia	HP:0001903,DOID:2355	0-6
Cardiac failure congestive * 1/48 (2.08%)	Adverse Events	3
Constipation * 2/48 (4.17%)	Adverse Events	4
constipation	HP:0002019,DOID:2089	0-12
Esophagitis * 1/48 (2.08%)	Adverse Events	5
esophagitis	HP:0100633,DOID:11963	0-11
Gastrointestinal hemorrhage * 1/48 (2.08%)	Adverse Events	6
gastrointestinal hemorrhage	HP:0002239	0-27
Non-Cardiac chest pain * 1/48 (2.08%)	Adverse Events	7
chest pain	HP:0100749	12-22
Pain * 1/48 (2.08%)	Adverse Events	8
pain	HP:0012531	0-4
Cholecystitis * 1/48 (2.08%)	Adverse Events	9
cholecystitis	HP:0001082,DOID:1949	0-13
Diverticulitis * 1/48 (2.08%)	Adverse Events	10
diverticulitis	DOID:7475	0-14
Cellulitis * 1/48 (2.08%)	Adverse Events	11
cellulitis	HP:0100658,DOID:3488	0-10
Gastroenteritis * 1/48 (2.08%)	Adverse Events	12
gastroenteritis	DOID:2326	0-15
